These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 27022464)

  • 1. Chronic P-glycoprotein inhibition increases the brain concentration of escitalopram: potential implications for treating depression.
    O'Brien FE; Moloney GM; Scott KA; O'Connor RM; Clarke G; Dinan TG; Griffin BT; Cryan JF
    Pharmacol Res Perspect; 2015 Dec; 3(6):e00190. PubMed ID: 27022464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram.
    O'Brien FE; O'Connor RM; Clarke G; Donovan MD; Dinan TG; Griffin BT; Cryan JF
    Behav Brain Res; 2014 Mar; 261():17-25. PubMed ID: 24280122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents.
    O'Brien FE; O'Connor RM; Clarke G; Dinan TG; Griffin BT; Cryan JF
    Neuropsychopharmacology; 2013 Oct; 38(11):2209-19. PubMed ID: 23670590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET.
    Syvänen S; Blomquist G; Sprycha M; Höglund AU; Roman M; Eriksson O; Hammarlund-Udenaes M; Långström B; Bergström M
    Neuroimage; 2006 Sep; 32(3):1134-41. PubMed ID: 16857389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
    Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
    J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.
    Bundgaard C; Eneberg E; Sánchez C
    Neuropharmacology; 2016 Apr; 103():104-11. PubMed ID: 26700248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment.
    Karlsson L; Carlsson B; Hiemke C; Ahlner J; Bengtsson F; Schmitt U; Kugelberg FC
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1636-44. PubMed ID: 23428338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
    Hendrikse NH; Schinkel AH; de Vries EG; Fluks E; Van der Graaf WT; Willemsen AT; Vaalburg W; Franssen EJ
    Br J Pharmacol; 1998 Aug; 124(7):1413-8. PubMed ID: 9723952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporin A has low potency as a calcineurin inhibitor in cells expressing high levels of P-glycoprotein.
    Fakata KL; Elmquist WF; Swanson SA; Vorce RL; Prince C; Stemmer PM
    Life Sci; 1998; 62(26):2441-8. PubMed ID: 9651111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.
    de Klerk OL; Willemsen AT; Roosink M; Bartels AL; Hendrikse NH; Bosker FJ; den Boer JA
    Int J Neuropsychopharmacol; 2009 Aug; 12(7):895-904. PubMed ID: 19224656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of P-glycoprotein function in the rat blood-brain barrier by distribution volume of [11C]verapamil measured with PET.
    Bart J; Willemsen AT; Groen HJ; van der Graaf WT; Wegman TD; Vaalburg W; de Vries EG; Hendrikse NH
    Neuroimage; 2003 Nov; 20(3):1775-82. PubMed ID: 14642487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier: an experimental PET study in rats.
    de Klerk OL; Bosker FJ; Willemsen AT; Van Waarde A; Visser AK; de Jager T; Dagyte G; den Boer JA; Dierckx RA; Meerlo P
    J Psychopharmacol; 2010 Aug; 24(8):1237-42. PubMed ID: 19942635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter?
    Clarke G; O'Mahony SM; Cryan JF; Dinan TG
    Hum Psychopharmacol; 2009 Apr; 24(3):217-23. PubMed ID: 19212940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
    Sasongko L; Link JM; Muzi M; Mankoff DA; Yang X; Collier AC; Shoner SC; Unadkat JD
    Clin Pharmacol Ther; 2005 Jun; 77(6):503-14. PubMed ID: 15961982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
    Zong J; Pollack GM
    J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The antidepressant- and anxiolytic-like effects following co-treatment with escitalopram and risperidone in rats.
    Kaminska K; Rogoz Z
    J Physiol Pharmacol; 2016 Jun; 67(3):471-80. PubMed ID: 27512008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier.
    Syvänen S; Hooker A; Rahman O; Wilking H; Blomquist G; Långström B; Bergström M; Hammarlund-Udenaes M
    J Pharm Sci; 2008 Dec; 97(12):5386-400. PubMed ID: 18384156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test.
    Zomkowski AD; Engel D; Gabilan NH; Rodrigues AL
    Eur Neuropsychopharmacol; 2010 Nov; 20(11):793-801. PubMed ID: 20810255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
    Hsiao P; Bui T; Ho RJ; Unadkat JD
    Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute and chronic escitalopram alter EEG gamma oscillations differently: relevance to therapeutic effects.
    Papp N; Vas S; Bogáthy E; Kátai Z; Kostyalik D; Bagdy G
    Eur J Pharm Sci; 2018 Aug; 121():347-355. PubMed ID: 29908300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.